The data confirms that the drug’s efficacy grows over time, outperforming the benchmarks set during an initial 16-week readout. Chief Executive Jorge Santos da Silva characterized the results as a validation of the treatment's competitive profile, noting consistent safety and dosing convenience alongside the sustained clinical response. The company now prepares to file a biologics license application with the U.S. Food and Drug Administration by the end of September, aiming for a market launch in 2025.

Investors responded sharply to the update, pushing the stock to $23.56. This rally adds to a volatile year for the biotech firm, which has seen its share price climb over 60% since January, recovering from a 57% decline over the trailing 12-month period. For patients, the stakes remain high; the condition causes irreversible tissue destruction and chronic, painful inflammatory lesions, leaving a significant gap in treatment options that MoonLake intends to fill.